This article has been taken from the 2025 Fleet200 Strategy Network Report, which details the key trends and developments that have taken - indeed, are taking - place among the company car, van and ...

Officers investigating a 21-year-old Ogden man who allegedly made violent, antisemitic threats online two days before Christmas ultimately found six finished pipe bombs throughout the man’s home, ...

Jeremy Ruckert doesn’t want to wake up anytime soon. The tight end, who was raised a Jets fan on Long Island and fulfilled his childhood dream when the team selected him in the 2022 draft, recommitted ...

WASHINGTON, Dec 12 (Reuters) - Republican leaders in the U.S. House of Representatives on Friday presented a healthcare proposal that leaves unresolved steep health insurance premium increases set to ...

Tether announced that its USDT stablecoin has been officially recognized as an Accepted Fiat-Referenced Token (AFRT) by the Abu Dhabi Global Market (ADGM) for use on multiple blockchains, including ...

Scott MacFarlane is CBS News' Justice correspondent. He has covered Washington for two decades, earning 20 Emmy and Edward R. Murrow awards. His reporting has resulted directly in the passage of five ...

Brian Cole Jr. admitted to investigators that he planted the bombs, sources say. The suspect accused of placing two pipe bombs outside the headquarters of the Republican and Democratic National ...

WASHINGTON ‒ President Donald Trump appeared ready to propose a policy framework to address health care costs that included extending subsidies in the Affordable Care Act, or ACA, set to expire at the ...

- PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (CTNM) (Contineum or the ...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...

- PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage ...

- PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter acuity (LCLA) SAN DIEGO, November 20, 2025--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: ...